Novo Nordisk President Urges Customer Focus to Reclaim Obesity Market Share from Eli Lilly

Novo Nordisk's president, Mike Doustdar, is pushing a customer-centric strategy to regain market share in the obesity drug market, where it has lost ground to Eli Lilly. The move reflects investor skepticism about leadership and intensifying competition in a segment projected to exceed $100 billion annually by 2030. The company's brand revitalization signals a strategic pivot, but execution remains uncertain.